This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Selinexor for advanced unresectable dedifferentiated liposarcoma

< Back

Selinexor for advanced unresectable dedifferentiated liposarcoma


Cancer and Palliative Care

May 2020

Selinexor is in clinical development for the treatment of adults with advanced unresectable dedifferentiated liposarcoma (DDLS). Liposarcoma is a malignancy of fat cells and represents the most common form of soft tissue sarcoma. The prognosis varies depending on tumour site, size, grade, and histologic subtype. DDLS occurs when a low-grade tumour changes and newer cells with higher grade arise in the tumour. DDLS is frequently found in the retroperitoneum and the extremities (arms and legs) and is characterised as a painless mass, though it can cause symptoms of obstruction, decrease in appetite and abdominal distention.

Selinexor works by selectively inhibiting nuclear export (SINE) compounds. By blocking a protein called Exportin 1 (XPO1), responsible for the transport of the major tumour suppressor proteins from the nucleus to the cytoplasm, the selinexor blocks the nuclear export of tumour suppressor, growth regulatory, and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anticancer activity in the cell. If licensed, selinexor will offer a treatment option for patients with advanced unresectable DDLS

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts